XTANDI® shows significant OS results in subjects with nmCRPC
Category: #healthcare  By Mateen Dalal  Date: 2020-02-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

XTANDI® shows significant OS results in subjects with nmCRPC

Japanese multinational pharmaceutical company, Astellas Pharma Inc. and U.S-based Pfizer Inc. have reportedly announced results of final OS (overall survival) analysis from the Phase 3 PROSPER clinical trial, which assessed XTANDI® (enzalutamide) plus ADT (androgen deprivation therapy) versus placebo plus ADT in nmCRPC (non-metastatic castration-resistant prostate cancer) male patients.

Reportedly, the results showed a substantial improvement in overall survival in nmCRPC patients who received XTANDI plus ADT. Overall survival was the main secondary endpoint of the clinical trial.

In a preliminary analysis, adverse effects were consistent with previously reported results from PROSPER. Meanwhile, complete efficacy and safety outcomes from the final PROSPER overall survival analysis will be shared soon.

For the record, XTANDI (enzalutamide) drug is an androgen receptor inhibitor directed for treating mCSPC (metastatic castration-sensitive prostate cancer) and CRPC (castration-resistant prostate cancer).

In 2018, Pfizer and Astellas revealed that the PROSPER clinical trial met its primary endpoint of MFS (metastasis-free survival). These outcomes were presented at the ASCO GU 2020 (Genitourinary Cancers Symposium 2020) and also published in the New England Journal of Medicine.

PROSPER safety and efficacy data at the time of the MFS assessment are included in the XTANDI labels Europe, Japan, and the U.S and are presently under review in China.

In addition to this development, Astellas Pharma and Seattle Genetics has recently announced updated outcomes from the Phase 1b/2 trial EV-103 in earlier untreated locally advanced or metastatic urothelial cancer patients who were disqualified for cisplatin-based chemotherapy treatment.

Reportedly, 45 patients were indicated with the combination of pembrolizumab and PADCEV™ (enfortumab vedotin-ejfv) and were assessed for efficacy and safety. After a median follow-up of around 11.5 months, the clinical trial results continues to meet outcome measures for safety and show positive clinical activity for this platinum-free combination in a first-line setting. 

Source Link - https://www.astellas.com/us/news/4811

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

AltPep Corporation raises USD 23.15 million in Series A funding round
AltPep Corporation raises USD 23.15 million in Series A funding round
By Mateen Dalal

According to reliable sources, U.S.-based privately held biomedical organization AltPep Corporation ...

Volvo to triple EV production volume at its Belgium facility from 2022
Volvo to triple EV production volume at its Belgium facility from 2022
By Mateen Dalal

Swedish luxury car manufacturer, Volvo AB has announced plans to triple electric vehicle production ...

Lenovo launches new AR smart glasses to improve industrial productivity
Lenovo launches new AR smart glasses to improve industrial productivity
By Mateen Dalal

In a bid to enhance efficiency among industrial workers amidst the alarming increase in distributed ...